186 related articles for article (PubMed ID: 11745233)
1. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.
Ribom D; Eriksson A; Hartman M; Engler H; Nilsson A; Långström B; Bolander H; Bergström M; Smits A
Cancer; 2001 Sep; 92(6):1541-9. PubMed ID: 11745233
[TBL] [Abstract][Full Text] [Related]
2. Role of [(11)C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours.
Cicuendez M; Lorenzo-Bosquet C; Cuberas-Borrós G; Martinez-Ricarte F; Cordero E; Martinez-Saez E; Castell-Conesa J; Sahuquillo J
Clin Neurol Neurosurg; 2015 Dec; 139():328-33. PubMed ID: 26588352
[TBL] [Abstract][Full Text] [Related]
3. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
[TBL] [Abstract][Full Text] [Related]
4. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography.
Shinozaki N; Uchino Y; Yoshikawa K; Matsutani T; Hasegawa A; Saeki N; Iwadate Y
J Neurosurg; 2011 Jun; 114(6):1640-7. PubMed ID: 21214332
[TBL] [Abstract][Full Text] [Related]
5. [MET-PET in low-grade glioma. Safe way to follow disease progression and treatment].
Smits A; Savitcheva I; Ribom D
Lakartidningen; 2007 Jan 31-Feb 6; 104(5):326-30. PubMed ID: 17328356
[No Abstract] [Full Text] [Related]
6. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma.
De Witte O; Levivier M; Violon P; Salmon I; Damhaut P; Wikler D; Hildebrand J; Brotchi J; Goldman S
Neurosurgery; 1996 Sep; 39(3):470-6; discussion 476-7. PubMed ID: 8875476
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas.
Takano K; Kinoshita M; Arita H; Okita Y; Chiba Y; Kagawa N; Fujimoto Y; Kishima H; Kanemura Y; Nonaka M; Nakajima S; Shimosegawa E; Hatazawa J; Hashimoto N; Yoshimine T
AJNR Am J Neuroradiol; 2016 Jan; 37(1):44-50. PubMed ID: 26381556
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pathology and survival by FDG PET in gliomas.
Padma MV; Said S; Jacobs M; Hwang DR; Dunigan K; Satter M; Christian B; Ruppert J; Bernstein T; Kraus G; Mantil JC
J Neurooncol; 2003 Sep; 64(3):227-37. PubMed ID: 14558598
[TBL] [Abstract][Full Text] [Related]
9. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine.
Derlon JM; Petit-Taboué MC; Chapon F; Beaudouin V; Noël MH; Creveuil C; Courtheoux P; Houtteville JP
Neurosurgery; 1997 Feb; 40(2):276-87; discussion 287-8. PubMed ID: 9007859
[TBL] [Abstract][Full Text] [Related]
10. Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.
Roessler K; Gatterbauer B; Becherer A; Paul M; Kletter K; Prayer D; Hoeftberger R; Hainfellner J; Asenbaum S; Knosp E
Minim Invasive Neurosurg; 2007 Oct; 50(5):273-80. PubMed ID: 18058643
[TBL] [Abstract][Full Text] [Related]
11. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
12. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma.
Kracht LW; Friese M; Herholz K; Schroeder R; Bauer B; Jacobs A; Heiss WD
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):868-73. PubMed ID: 12692687
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography with injection of methionine as a prognostic factor in glioma.
De Witte O; Goldberg I; Wikler D; Rorive S; Damhaut P; Monclus M; Salmon I; Brotchi J; Goldman S
J Neurosurg; 2001 Nov; 95(5):746-50. PubMed ID: 11702862
[TBL] [Abstract][Full Text] [Related]
14. Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.
Ninatti G; Sollini M; Bono B; Gozzi N; Fedorov D; Antunovic L; Gelardi F; Navarria P; Politi LS; Pessina F; Chiti A
Neuro Oncol; 2022 Sep; 24(9):1546-1556. PubMed ID: 35171292
[TBL] [Abstract][Full Text] [Related]
15. 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas.
Gumprecht H; Grosu AL; Souvatsoglou M; Dzewas B; Weber WA; Lumenta CB
Zentralbl Neurochir; 2007 Feb; 68(1):19-23. PubMed ID: 17487804
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of PET using 11C-methionine in patients with untreated cerebral gliomas].
Svortsova TIu; Brodskaia ZL; Gurchin AF; Gaĭdaenko KP
Zh Vopr Neirokhir Im N N Burdenko; 2011; 75(4):10-6; discussion 16. PubMed ID: 22379848
[TBL] [Abstract][Full Text] [Related]
17. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.
Ceyssens S; Van Laere K; de Groot T; Goffin J; Bormans G; Mortelmans L
AJNR Am J Neuroradiol; 2006 Aug; 27(7):1432-7. PubMed ID: 16908552
[TBL] [Abstract][Full Text] [Related]
18. 11C-methionine PET for differential diagnosis of low-grade gliomas.
Herholz K; Hölzer T; Bauer B; Schröder R; Voges J; Ernestus RI; Mendoza G; Weber-Luxenburger G; Löttgen J; Thiel A; Wienhard K; Heiss WD
Neurology; 1998 May; 50(5):1316-22. PubMed ID: 9595980
[TBL] [Abstract][Full Text] [Related]
19. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.
Watanabe A; Muragaki Y; Maruyama T; Shinoda J; Okada Y
J Neurooncol; 2016 Feb; 126(3):577-83. PubMed ID: 26612734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
